The Associated Press
updated 10/6/2003 10:25:46 AM ET 2003-10-06T14:25:46

U.S. regulators have told European drugmaker AstraZeneca Plc to stop circulating promotions that claim its antibiotic, Merrem, is effective against drug-resistant infections.

  1. Don't miss these Health stories
    1. Splash News
      More women opting for preventive mastectomy - but should they be?

      Rates of women who are opting for preventive mastectomies, such as Angeline Jolie, have increased by an estimated 50 percent in recent years, experts say. But many doctors are puzzled because the operation doesn't carry a 100 percent guarantee, it's major surgery -- and women have other options, from a once-a-day pill to careful monitoring.

    2. Larry Page's damaged vocal cords: Treatment comes with trade-offs
    3. Report questioning salt guidelines riles heart experts
    4. CDC: 2012 was deadliest year for West Nile in US
    5. What stresses moms most? Themselves, survey says

THE FOOD and Drug Administration, in a letter to the company posted on the agency’s Web site Monday, objected to physician-directed sales materials with the claim “Attacking the Tide of Resistance” and other suggestions that Merrem could fight bacteria that did not succumb to other treatments.

“FDA is not aware of substantial evidence or substantial clinical experience to support this claim of clinical efficacy against resistant pathogens,” the agency said in the letter, which was dated Oct. 3.

In some cases, AstraZeneca cited data showing Merrem worked against resistant bacteria in laboratory tests. That type of data is “not an adequate basis on which to accurately predict the clinical effectiveness of an antimicrobial agent,” the FDA said.

AstraZeneca, Europe’s No. 2 drug maker, is evaluating the letter, company spokeswoman Cindy Callaghan said.

“We will work cooperatively with the FDA to resolve the matter,” she said.

The emergence of drug-resistant bacteria is a major public health concern as more pathogens become difficult to treat. Inappropriate prescribing is considered a contributing factor.

Sign up for our health e-newsletter
Merrem, which is given intravenously, was approved in 1996 for treating abdominal infections and bacterial meningitis caused by certain strains of pathogens. It is not cleared for treating drug-resistant bacteria.

“To suggest that Merrem I.V. is effective for the treatment of drug-resistant pathogens may promote inappropriate prescribing,” the FDA letter said.

© 2003 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters.

© 2005 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments